Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27103043 | 0.95 | MPO (0.41) | OPRM1MPOMAPTSMN1; SMN2KDM4E | |
| SCHEMBL23225650 | 0.95 | MPO (0.41) | OPRM1MPOMAPTSMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL29773033 | 0.85 | MPO (0.43) | OPRM1MPOALDH1A1 | |
| SCHEMBL23225718 | 0.83 | MPO (0.49) | OPRM1MPOMAPTSMN1; SMN2GAA | |
| SCHEMBL27141256 | 0.83 | OPRM1 (0.37) | OPRM1MPO | |
| SCHEMBL27141261 | 0.83 | OPRM1 (0.37) | OPRM1MPO | |
| SCHEMBL23217909 | 0.82 | MPO (0.46) | OPRM1MPOSMN1; SMN2GAAKDM4E | |
| SCHEMBL27102034 | 0.82 | MPO (0.46) | OPRM1MPOSMN1; SMN2GAAKDM4E | |
| SCHEMBL23225720 | 0.80 | MPO (0.46) | OPRM1MPOALDH1A1TSHR | |
| SCHEMBL23217985 | 0.79 | MPO (0.48) | OPRM1MPOALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| EP-4041735-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | Biohaven Therapeutics Ltd. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | OPRM1 1161/4885MPO 1/4885MAPT 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.